检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib

Severine Guiu Lahaye,Judith Balmana Gelpi, Ludovic Gauthier,Frederic Bigot,Anthony Goncalves,Jean-Sebastien Frenel,Thomas Bachelot,Florence Dalenc,Audrey Mailliez,Camille Chakiba,Dominique Genet,Nathalie Dohollou,Isabelle Desmoulins,Jean-Luc Re Canon,Clara Guyonneau, Adrien Buisson,Louise-Marie Chevalier,Suzette Delaloge,Philippe Follana

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 0|浏览8
暂无评分
关键词
breast cancer,durvalumab,olaparib,er-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要